20 related articles for article (PubMed ID: 38661028)
1. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
[TBL] [Abstract][Full Text] [Related]
2. Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells.
Park SH; Lee DH; Kim JL; Kim BR; Na YJ; Jo MJ; Jeong YA; Lee SY; Lee SI; Lee YY; Oh SC
Oncotarget; 2016 Sep; 7(37):59503-59518. PubMed ID: 27517746
[TBL] [Abstract][Full Text] [Related]
3. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
Matsuura K; Huang NJ; Cocce K; Zhang L; Kornbluth S
Oncogene; 2017 Mar; 36(12):1698-1706. PubMed ID: 27721409
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA LINC00152 promotes cell proliferation through competitively binding endogenous miR-125b with MCL-1 by regulating mitochondrial apoptosis pathways in ovarian cancer.
Chen P; Fang X; Xia B; Zhao Y; Li Q; Wu X
Cancer Med; 2018 Sep; 7(9):4530-4541. PubMed ID: 30030896
[TBL] [Abstract][Full Text] [Related]
6. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
[TBL] [Abstract][Full Text] [Related]
7. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1.
Cai Y; Li Y; Xu Y; Yang W; Huang M
FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.
Mittal P; Singh S; Sinha R; Shrivastava A; Singh A; Singh IK
Int J Biol Macromol; 2021 Sep; 187():999-1018. PubMed ID: 34339789
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 ubiquitination and destruction.
Inuzuka H; Fukushima H; Shaik S; Liu P; Lau AW; Wei W
Oncotarget; 2011 Mar; 2(3):239-44. PubMed ID: 21608150
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]